Oncology Treatment Market | DelveInsight Business Research
An in-depth Assessment of the Top Drugs Launched by Leading Global Companies in the First Half of 2021 (H1)
oncological-drugs-to-be-launch-in-2022
Most Promising Oncological Drugs Expe...

The innovation in the oncology drug pipeline has resulted in a record number of FDA and EU approvals in rec...

antibody-drug-conjugate-pipeline
Insights into the Evolving Landscape ...

In the year 2000, the first-ever Antibody-drug Conjugate (ADC) - Mylotarg, was launched by Pfizer and was c...

pharma-news-for-noxxon-nuvalent-stryker-exact-sciences
Noxxon’s NOX-A12 clinical trial; Exac...

Noxxon continues enrolment in a glioblastoma therapy trial Noxxon Pharma continues subject enrolment in the...

metastatic-colorectal-cancer-treatment-market
Novel and Emerging Metastatic Colorectal Cancer Treatment Drugs Anticipated to Change Market Dyna...

Colorectal cancer is a disease in which malignant (cancer) cells form in the tissues of the colon or the rectum. Colorectal Cancer is the third most lethal and fourth most commonly diagnosed cance...


drugs-launched-in-second-half-2021
Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021

Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did not cease developing new treatments this year. The US Food and Drug Administration maintained a rapid rate o...


pharma-news-for-accutar-bio-thera-nykode-heat-biologics-elusys
Accutar’s Phase I clinical trial for AC0176; Bio-Thera’s cancer drug, BAT6005; Nykode...

FDA approves IND application of Accutar for a prostate cancer treatment trial The US Food and Drug Administration (FDA) has granted Accutar Biotechnology’s Investigational New Drug (IND) applic...


pharma-news-for-biogen-eisai-quidel-accutar-boehringer
Biogen-Eisai’s Aduhelm; Quidel acquires Ortho Clinical Diagnostics; Accutar Biotechnology’s...

Biogen-Eisai's potential Aduhelm sequel drug secured speedy review by FDA Biogen and Eisai’s Alzheimer’s disease treatment-in-waiting, lecanemab, has been secured a fast-track tag by the FDA, s...


Diffuse Large B-cell Lymphoma Highlights
Major Highlights of Diffuse Large B-cell Lymphoma/ Large B-cell lymphoma (LBCL) in ASH 2021

ASH 2021,which ended on December 14, 2021, was a premier event in malignant and non-malignant hematology. Like every year, key pharma players took center stage and shared new data regarding the de...


biosimilar-market-trends
Analyzing the Key Trends Driving the Biosimilar Market Growth

The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a compelling economic value proposition. This has been a considerable element in expanding the biosimilar mark...


Editor's Pick
22 Healthcare Trends & Innovations to Watch in 2022 and Beyond

With the advent of new-age healthcare industry trends that are evident as of now, there...

Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021

Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did...

Analyzing the Key Trends Driving the Biosimilar Market Growth

The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a...

CAR-T Cell Therapy aka Miraculous Technology: Mapping the Market, Approved Th...

Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative pot...

Myelodysplastic Syndromes (MDS): Key Pharma Players Unveiling Updated Finding...

There has been limited progress in the approval of novel agents in MDS. It has been a l...